Efficacy and safety analysis of treatment in patients with EGFR-mutated advanced NSCLC who progressed on TKIs: a systematic review and meta-analysis.

ABSTRACT:

Background

The treatment of patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) whose disease progresses after tyrosine-kinase inhibitors (TKIs) treatment has become a research hotspot.

Objective

To identify effective and safe treatment options for patients with EGFR-mutated advanced NSCLC who progressed on TKIs.

Methods

We searched databases including PubMed, Cochrane Library, and major international conference abstracts (2018-2023) to identify phase II/III randomized controlled trials (RCTs) and single-arm studies of EGFR-mutated advanced NSCLC post-TKI progression from April 2018 to June 2024. Outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and grade ≥3 ad

SUBMITTER: Zhang S 

PROVIDER: S-EPMC12602472 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature